Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.71 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755027 | 1.00 | FLT3 (0.71) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL13080901 | 1.00 | FLT3 (0.71) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL29638292 | 0.91 | KDR (0.72) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL14674418 | 0.91 | KDR (0.72) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL14674419 | 0.91 | KDR (0.72) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL3283850 | 0.90 | RPS6KA3 (0.66) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL3283744 | 0.90 | RPS6KA3 (0.66) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL3283740 | 0.90 | RPS6KA3 (0.66) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL29638300 | 0.90 | FLT3 (0.61) | FLT3LRRK2KDRMEN1KMT2A | |
| SCHEMBL14674714 | 0.90 | FLT3 (0.61) | FLT3LRRK2KDRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | claimed |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | US | claimed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | FLT3 3095/4885LRRK2 39/4885KDR 3586/4885 |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | ERBB2, ABL1, IGF1R | FLT3 16/4885LRRK2 19/4885KDR 81/4885 |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, BDNF, HTT | FLT3 3151/4885LRRK2 26/4885KDR 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.